Number Structure: Growth and Downfall
- Current price (Oct 2025): $0.365
- Market cap: $21.6M
- Net loss (Q1 2025): $14.2M (versus $10.7M Q1 2024)
- Cash (Q1 2025): $60.5M
- Debt/Equity: 66.87x
- Shares out: 59.25M
- 52-week range: $0.22–$3.09
- Analyst 12-month price target: $1.52 to $7.35
- Product pipeline: EO-3021 program discontinued (Mar 2025); EO-1022 now lead asset (HER3 ADC for solid tumors)
Growth factors:
- Pipeline advancement (EO-1022), strong cash reserves for operations
- Analyst ratings improving; 60% Buy, 30% Hold
Downfall risks: - Persistent net loss, low share price, risk of further dilution, competitive clinical landscape
HTML Price Prediction Table
Elevation Oncology (ELEV) Monthly Price Prediction 2025–2030
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 0.39 | 0.42 | 0.50 | 0.55 | 0.62 | 0.70 | 0.75 | 0.80 | 0.85 | 0.90 | 1.05 | 1.25 |
| 2026 | 1.35 | 1.45 | 1.55 | 1.65 | 1.80 | 1.95 | 2.05 | 2.20 | 2.35 | 2.50 | 2.65 | 2.75 |
| 2027 | 2.80 | 2.85 | 2.90 | 2.98 | 3.10 | 3.15 | 3.20 | 3.25 | 3.35 | 3.45 | 3.60 | 3.70 |
| 2028 | 3.80 | 4.00 | 4.20 | 4.35 | 4.50 | 4.60 | 4.75 | 4.85 | 5.00 | 5.10 | 5.15 | 5.20 |
| 2029 | 5.35 | 5.50 | 5.70 | 5.84 | 6.00 | 6.10 | 6.25 | 6.40 | 6.55 | 6.70 | 6.85 | 7.00 |
| 2030 | 7.12 | 7.22 | 7.32 | 7.40 | 7.48 | 7.60 | 7.72 | 7.85 | 7.95 | 8.00 | 8.10 | 8.19 |
Five Key Graphs to Represent Growth and Downfall
- Line Chart: Monthly Price Prediction (2025–2030)
- Uptrend from $0.39 to $8.19, with steepest gain in early years, stabilizing after 2028.
- Bar Chart: Annual Returns
- Shows annual percent returns with biggest gains expected in 2026, moderating thereafter.
- Drawdown Chart:
- Marks price drops during pipeline setbacks or financing stress, most acute pre-2025.
- Cash & Net Loss Line Chart:
- Cash reserves vs. net loss per quarter, reflecting operational burn and financing risk.
- Volatility Chart:
- Maps monthly price changes (standard deviation), higher in 2025–2026, stabilizing after 2028.
Calculation Model
Projections use a blend of:
- Analyst consensus targets
- Compound rates for bullish periods (~15–30% p.a. for 2026–2027), more moderate growth in later years.
- Current financial structure, pipeline progress, and competitive factors.
Pn+1=Pn×(1+r)
Rates are moderated for operational events (asset sales, dilution, R&D progress).
Disclaimer
This content is informational only. ELEV is high-risk; price forecasts are speculative and contingent on clinical, regulatory, and market events. Historical underperformance does not guarantee future outcomes. Consult with a licensed financial advisor before investing.